bluuebunny/crossref_metadata_2025_split huggingface dataset:
Follicular mantle zone cell subpopulations detected by monoclonal antibody SN3
Authors: Barcos M. , Pollard C. , Fukukawa T. , Seon B. K. 
Published: February 2007

AbstractA monoclonal antibody, SN3, has been prepared against a cell membrane fraction of the pre‐B leukemic cell line NALM‐1. By radioimmunoassay, SN3 reacted with four of four non‐T/non‐B, two of two pre‐B and one of three leukemic B cell lines. The reagent was unreactive, however, with established leukemic T and myelomonocytic cell lines or normal B cell lines. On immunohistochemical assays on frozen sections of nine reactive lymph nodes and three spleens, SN3 showed a preferential binding to 50–95 per cent mantle zone (MZ) cells and 5–20 per cent interfollicular or red pulp B‐lymphocytes. This was uninhibited by pre‐incubation with heterologous anti‐HLA‐DR or anti‐δ reagents. SN3 was unreactive with normal germinal centre (GC), epidermal or Langherhans cells but did react with less than 1 per cent thymic B‐lymphocytes. In eight follicular small cleaved cell lymphomas tested SN3 exhibited three patterns of reactivity: (1) peripheral follicular, (2) combined peripheral and central follicular, and (3) combined follicular and interfollicular. Three follicular lymphomas were essentially SN3‐. In three diffuse small lymphocytic lymphomas, SN3 showed patchy areas of reactivity unassociated with proliferation centres. In four diffuse B‐cell lymphomas (one mixed small and large cell, two large non‐cleaved cell, and one small non‐cleaved (Burkitt) cell), SN3 reactivity was uniformly distributed in the majority (60–90 per cent) of the cells. SN3 was unreactive with one diffuse B‐large cell lymphoma, three nodal T‐cell lymphomas and three cases of mycosis fungoides. The findings indicate that (1) SN3 detects an antigen that is present in subpopulations of normal MZ cells, (2) the antigen is also detected in GC cells undergoing lymphomatous transformation but is not readily detected in normal GC cells, and (3) the antigen is also expressed in subpopulations of diffuse B‐ but not T‐cell lymphomas.
Glucose‐6‐phosphatase activity of reed‐sternberg and hodgkin cells
Authors: Pangalis Gerassimos A. , Tsavaris Nikolaos B. 
Published: February 2007

AbstractThe glucose‐6‐phosphatase (G‐6‐Pase) enzyme cytochemical reaction was successfully applied on lymph node imprints, after introducing the appropriate modifications related to fixation and to composition of the substrate solutions. Using this method we studied the G‐6‐Pase cytochemical profile on lymph node imprint preparations from 30 patients with Hodgkin's disease. Three cases had the histologic subtype of lymphocyte predominance, 14 the modular sclerosis, 11 the mixed cellularity and two the lymphocyte depleted. A strong G‐6‐Pase positivity was found in the Reed‐Sternberg (RS) and Hodgkin cells of the mixed cellularity type, while the RS and Hodgkin cells of the other subtypes were less positive. The rest of the cell population present were G‐6‐Pase negative, with the exception of plasma cells which exhibited a strong G‐6‐Pase cytoplasmic positivity. We concluded from our study that RS and Hodgkin cells resemblance to plasma cells and therefore they may be of B‐cell origin. In addition it appears that RS and Hodgkin cells express different functional properties in the various histologic subtypes of the disease.
The role of eosinophil in regulation of granulopoiesis
Authors: Gardner Renee V. , Tebbi Cameron K. , Chervinsky David , McGarry Michael 
Published: February 2007

AbstractAn association between eosinophilia and neutropenia has been observed in a number of clinical conditions. To probe the role of eosinophils in granulopoiesis, marrow and peritoneal eosinophils, obtained from Schistosoma mansoni‐infected mice, were separated and purified. Normal bone marrow cells were cultured in semisolid culture medium in concentrations ranging from 5 × 104 to 5 × 105, with and without added eosinophils. To examine whether high prostaglandin E (PGE) content of eosinophils affects granulopoiesis, idomethacin was added to duplicate marrow cultures containing eosinophils. The addition of eosinophils to normal syngeneic marrow culture caused a significant inhibition of granuloyte‐macrophage colony formation (CFU‐GM) in culture. This suppressive effect was reversible upon addition of indomethacin. These findings suggest that eosinophils, in vitro, are capable of inhibition of granulopoiesis. The reversal of this effect by indomethacin indicates that this suppression may be prostaglandin mediated.
Hypoplastic acute leukemia: Review of 70 cases with multivariate regression analysis
Authors: Berdeaux Donald H. , Glasser Lewis , Serokmann Ruth , Moon Thomas , Durie Brian G. M. 
Published: February 2007

AbstractBetween 1971 and 1984, 22 of 190 adult patients (11·6 per cent) with acute leukemia seen at the University of Arizona had hypocellular acute leukemia (HAL), defined as lymphoblasts or myeloblasts (plus atypical promyelocytes) of ≧30 per cent, but marrow cellularity of the core biopsy or clot section of ≧50 per cent based on a 1000 point count. These 22 patients with HAL plus the 48 previously published patients with well documented HAL (combined series of 70 patients) were evaluated in detail with multivariate analysis. The median leukocyte count was 2700/μL, hemoglobin of 8μ2g/dl, and platelet count 63000/μL. Circulating blasts were noted in 27 of 52 patients (52 per cent). Twenty‐seven of 34 patients (79 per cent) had abnormal cytogenetics. The overall median survival was 8 months (range: 0·1–48). The median survival for the 22 patients managed with supportive care alone was 4 months, 6 months for the 16 patients treated with non‐aggressive induction therapy, and 13 months for the 32 patients treated with aggressive induction therapy (p<0·02 versus other categories). Multivariate analysis confirmed that aggressive induction therapy was a major favourable prognostic factor (p=0·016). Multivariate analysis of the aggressively induced patients revealed that younger patients (≧65; p=0·04) and patients with no AHD (p=0·09) lived longer. Thus, aggressive remission induction can be attempted in HAL and appears to contribute to prolonged survival especially under age 65 years.
Non‐secretory multiple myeloma: A report of 13 cases with a review of the literature
Authors: Smith David B. , Harris Martin , Gowland Eric , Chang James , Scarffe J. Howard 
Published: February 2007

AbstractThe clinical features of 13 patients with non‐secretory myloma from a series of 172 consecutive multiple myelomas are presented. The non‐secretors survived significantly longer that the secretors, median 46 months versus 21 months (p<0·01). Non‐secretory myeloma was associated with a higher incidence of neurological presentation, minimal lytic bone disease, a lower median percentage of plasma cells in the marrow and a lower incidence of hypogammaglobulinaemia. The median survival of the non‐secretors with minimal lytic bone lessions was 74 months compared to 21 months for those with extensive bone disease. The superior survival of non‐secretors is thus thought to be due to earlier presentation possibly as a result of a tendency to form symptomatic local tumoursRetrospective immunoperoxidase staining of stored tissue was performed in nine cases. In only one of these was a monoclonal immunoglobulin not detected indicating that true ‘non‐production’ is rare. In four patients who produced a biochemically detectable paraprotein during the course of their disease and in whom immunoperoxidase data was available the immunoglobulin was of the same type. Immunoperoxidase staining may help in the initial diagnosis of non‐secretory myeloma but did not contribute any prognostic information.
The myelodysplastic syndrome—a practical guide
Authors: Hamblin T. J. , Oscier D. G. 
Published: February 2007

AbstractThe term ‘myelodysplastic syndrome’ (MDS) is of recent coinage but neatly describes a well‐recognized group of conditions. In the past they have been confusingly classified by a variety of terms from ‘refractory anaemia’ to ‘pre‐leukaemia’. There have been several excellent reviews (Galton, 1984, 1986; Francis and Hoffbrand, 1985; Jacobs, 1985) which comprehensively cover the history and development of MDS as a concept and describe recent advances both in diagnosis and treatment and in the understanding of the pathogenesis. The purpose of this paper is not to rival these reviews in exhaustive detail, but to present a practical guide to the diagnosis and management of MDS as it presents to the working physician. In doing this we draw heavily on experience of 238 cases of MDS seen in our own unit in the past 6 years.
In vitro production of granulocyte–macrophage colony‐stimulating activity by murine bone marrow and spleen following vinblastine administration IN VIVO
Authors: Williams Douglas E. , Chervinsky David S. , Orsini Frank R. , Tebbi Cameron K. , Fitzpatrick John E. 
Published: February 2007

AbstractThe production of granulocyte–macrophage colony‐stimulating activity (CSA) by isolated murine femur shafts, non‐dispersed bone marrow and spleens was assessed following administration of Vinblastine (VLB). These organs were removed from 2 h to 10 days post‐VLB and allowed to condition endotoxin‐free medium for 48 h. CSA activity was assessed using a soft agar cloning system. The data demonstrate that CSA elaboration was maximal 24 h post‐VLB, corresponding to the nadir of bone marrow GM‐CFC, and 6 h after splenic reached a minimum. No relationship between peripheral blood granulocyte count or serum endotoxin levels were observed.
Peripheral blood stem cell autografting
Authors: Bell A. J. , Hamblin T. J. , Oscier D. G. 
Published: February 2007

AbstractTransplantation of haemopoietic stem cells provides a means whereby patients with malignant disease may be treated with increased doses of chemotherapy or chemoradiotherapy. Until recently, the bone marrow has been the sole source of these cells. However, haemopoietic progenitors can also be demonstrated in the blood and it has been known for more than twenty years that peripheral blood mononuclear cells are capable of repopulating the marrow in animals. This phenomenon has recently been reproduced in man. The use of peripheral blood rather than bone marrow for autologous stem cell rescue may have advantages in terms of ready access, availability in patients with compromised pelvic bone marrows, a lower risk of tumour contamination and more rapid granulocyte and immune recovery. However, clinical experience with peripheral blood stem cell autografting is still very small. This review discusses the characteristics of circulating stem cells, the methods by which they can be collected and stored and the information which has come from recent studies of their transplantation in man.
Immunoprecipitation of the interleukin‐2 receptor from Hodgkin's disease derived cell lines by monoclonal antibodies
Authors: Schwarting R. , Gerdes J. , Ziegler A. , Stein H. 
Published: February 2007

AbstractThe nature of Hodgkin and Reed‐Sternberg (H–RS) cells and their normal counterpart remains a matter of controversy. Our recent investigations have suggested that H–RS‐cells derive from certain activated lymphocytes of either B or T cell origin. In keeping with this concept, we were able to demonstrate that in the majority of cases of Hodgkin's disease the interleukin‐2 receptor (IL2‐R) was detectable on H–RS‐cells by three monoclonal antibodies (anti‐Tac, Tü69 and ACT‐1) with the sensitive alkaline phosphatase anti‐alkaline phosphatase (APAAP) tissue staining procedure. In extension of these studies, we precipitated IL2‐R antigen from two established permanent cell lines (L540 and L591) derived from patients with Hodgkin's disease. Although these cell lines are different in nature, in that the L540 line shows rearrangement for the T cell receptor beta chain gene and the L591 line displays rearrangement for immunoglobulin genes (gamma heavy and lambda light chain), the antigen precipitated by monoclonal antibodies against IL2‐R exhibited a molecular weight of approximately 53 kd on the L591 line and 58 kd on the L540 line. Thus, these data strongly support the view that the labelling of H–RS‐cells in tissue sections for IL2‐R was not merely due to cross‐reactivities of the two anti‐IL2‐R antibodies with a determinant of an unrelated structure but represents true IL2‐R molecules.
Opec chemotherapy (vincristine, prednisolone, etoposide and chlorambucil) for refractory and recurrent Hodgkin's disease
Authors: Barnett M. J. , Man A. M. , Richards M. A. , Waxman J. H. , Wrigley P. F. M. , Lister T. A. 
Published: February 2007

AbstractFifteen adults with refractory or recurrent Hodgkin's disease were treated with a combination of: vincristine, prednisolone, etoposide and chlorambucil (OPEC). All had previously received mustine, vinblastine, procarbazine and prednisolone (MVPP) and seven had subsequently been treated with alternative regimens. Responses were achieved in four, but complete remission in only one. Toxicity was considerable and five died of treatment related complications. Only two are alive (one in complete remission) more than three years after therapy. The toxicity of the OPEC regimen outweighed its benefit in this group of poor prognosis patients.
Leu M‐1 antigen: Comparative expression in hodgkin's disease and T cell lymphoma
Authors: Strauchen J. A. , Breakstone B. 
Published: February 2007

AbstractExpression of the granulocyte antigen Leu M‐1 is characteristic of Reed–Sternberg cells and the related mononuclear cells of Hodgkin's Disease. Leu M‐1 has been proposed as a specific immunological marker for Hodgkin's Disease which may be otherwise difficult to distinguish both morphologically and immunologically from non Hodgkin's lymphomas of peripheral T‐cell type. In the present study the comparative expression of Leu M‐1 in Hodgkin's Disease and peripheral T cell lymphoma was studied in a series of 43 cases including 25 cases of Hodgkin's Disease and 18 cases of immunologically documented peripheral T cell lymphoma. Leu M‐1 staining by avidin‐biotin‐peroxidase complex technique in acetone fixed frozen sections was observed in 22 of 25 cases of Hodgkin's Diseases, (2 of 3 cases of lymphocyte predominant Hodgkin's Disease and 1 case of mixed cellularity were negative) and in 4 of 18 cases of peripheral T cell lymphoma. The pattern of staining in the peripheral T cell lymphomas was indistinguishable from that observed in Hodgkin's Disease in 2 of the cases. Leu M‐1 staining appears to be of limited diagnostic value in the differential diagnosis of Hodgkin's Disease and T cell lymphoma. Absence of Leu M‐1 staining in frozen tissue however, makes a diagnosis of Hodgkin's Disease (with the exception of the lymphocyte predominant form) unlikely.
Long‐term results of treatment of patients with follicular lymphomas
Authors: Kalter S. , Holmes L. , Cabanillas F. 
Published: February 2007

AbstractThe management of patients with follicular lymphoma is controversial, particularly in those with follicular small cleaved cell (FSCC) or nodular poorly differentiated lymphoma (NPDL). Some advocate no treatment until symptoms arise, while others prefer to treat with intensive combination regimens and others with single agents. We reviewed the long‐term effects of two types of combination chemotherapy on relapse‐free survival and survival on 91 patients (88 were stages III–IV) who had received no previous chemotherapy. Those patients with FSCC lymphoma obtaining a complete remission had a significantly longer median survival than did those obtaining a partial remission (13 years versus 2 years). An adriamycin‐containing regimen appeared to be the key factor in obtaining a complete remission in FSCC after taking into consideration prognostic factors. Not only was the complete response rate significantly higher for patients receiving adriamycin, but so too was the median survival and relapse‐free survival. BCG immunotherapy appeared to be important in preventing relapse in some of the complete responders with NPDL who received adriamycin.
Reliability and consistency of bone marrow assessments of complete remission in acute myelogenous leukaemia
Authors: Birkhead B. G. , Salt D. , Jackson R. R. P. 
Published: February 2007

AbstractAn experiment is described which was designed to investigate the level of variability in the assessment of bone marrow remission in Acute Myelogenous Leukaemia (AML). The inter‐rater reliability and individual consistency of three haematologists at St Bartholomew's Hospital, London, are analysed using their assessments of cellularity, percent blast cells and marrow status for fifty bone marrow samples.
Lymph node architecture in Hodgkin's disease: Evidence for the role of the composite nodule in nodular sclerosing Hodgkin's disease
Authors: Van Parys G. , De Wolf‐Peeters C. , Van Den Oord J. J. , Desmet V. J. 
Published: February 2007

AbstractThe presence or absence of composite nodules, corresponding to recently described structural and functional units in the human reactive lymph node, was investigated in 22 lymph nodes involved by Hodgkin's disease using in situ immuno‐ and enzymehistochemical techniquesIn 10/13 cases of nodular sclerosing subtype, typical composite nodules composed of adjacent B‐ and T‐domains and surrounded by a rim of high endothelial venules were recognized. In association with these venules, a concentrical rim of fusiform shaped Alk Phase+ fibroblastic reticulum cells was observedReed‐Sternberg cells and their morphological variants were exclusively found in the T‐area of these composite nodulesIn 5/6 cases of mixed cellularity Hodgkin's disease, B lymphoid follicles were apparent. No vascular relationship with the tumourally involved areas was noticedIn the remaining cases, including all cases of lymphocytic depletion Hodgkin's disease only scattered B cell clusters were recognizedOur observations indicate the persistence of an organoid structure, i.e. the composite nodule in nodular sclerosing Hodgkin's Disease (HD).
Chromosomal abnormalities in non‐hodgkin lymphoma with peripheral t‐cell type: Effect of HTLV‐I infection
Authors: Sanada Isao , Ishii Toshinori , Matsuoka Masao , Kumagai Etsuko , Nishimura Hiromichi , Yamaguchi Kazunari , Takatsuki Kiyoshi 
Published: February 2007

AbstractCytogenetic studies were done in lymph node and peripheral leukemic cells from sixteen patients with non‐Hodgkin lymphoma with peripheral T‐cell type. Ten patients were positive for human T‐cell leukemia virus I (HTLV‐I) proviral DNA in tumour cells and six were negative. The former group had a higher tendency for leukemic conversion and poorer prognosis than the latter. However, no definite difference on the numerical and structural chromosomal abnormalities between these two groups was found. The most frequent chromosome abnormalities: 14p +, 14q+ and No. 6 abnormalities were detected in both groups. These results may indicate that HTLV‐I does not play a specific role in chromosome abnormalities of non‐Hodgkin lymphoma with peripheral T‐cell type.
Peripheral T‐cell lymphoma: A clinicopathologic study of 42 cases
Authors: Weisenburger Dennis D. , Linder James , Armitage James O. 
Published: February 2007

AbstractWe analysed the clinical and pathologic features of 42 patients with immunologically confirmed peripheral T‐cell lymphoma. The median age was 60 years and the male to female ratio was 1:1. A prior lymphoprolifera‐tive or autoimmune disorder was present in 14 per cent of the patients. Signs of advanced disease were usually present from the onset, such as B symptoms (55 per cent), generalized lymphadenopathy (57 per cent), stage III/IV disease (62 per cent), and elevated levels of serum lactate dehydrogenase (68 per cent). Primary extranodal disease (14 per cent), hepatomegaly (12 per cent), splenomegaly (12 per cent), lung/pleural involvement (12 per cent), skin involvement (21 per cent), and bone marrow involvement (28 per cent) were uncommon. Lymphocytopenia was present in 64 per cent of the patients, and none of nine patients tested were serologically positive for human T‐cell leukemia/lymphoma virus (HTLV‐I) infection. Among 38 patients receiving combination chemotherapy, 20 (53 per cent) achieved a complete remission. The actuarial median survival of all patients was 17 months. Age greater than 60 years and stage III/IV disease predicted a poor clinical outcome, whereas the large cell histological subtype predicted a favourable outcome. Prospective clinical studies using uniform treatments and a uniform histologic classification scheme are needed to confirm these findings.
Auer rods in the acute myeloid leukemias: Frequency and methods of demonstration
Authors: Jain N. C. , Cox C. , Bennett J. M. 
Published: February 2007

AbstractOne hundred and twenty‐five cases of acute myeloid leukemia (AML) were reviewed for the presence of Auer rods by two peroxidase methods. The percentage of Auer rods recognized by Wright‐Giemsa (WG) staining was 20·8% but three times higher by peroxidase staining techniques using either benzidine base as a substrate (PO method) or 3,3′‐diaminobenzidine as a substrate (DAB method). Both PO and DAB methods were equally sensitive in identifying Auer rods, the higher percentage being in FAB types M2 and M4 and lower in M1, M3, and MSB, with none in MSA. Cell counts of at least 100 cells were as accurate as counting cells up to a total of 1000 consecutive blasts.
Allogeneic and autologous bone marrow transplantation for acute leukemia and malignant lymphoma: Current status
Authors: Petersen F. B. , Buckner C. Dean 
Published: February 2007

AbstractThe current status of autologous and allogeneic marrow transplantation for acute leukemias and malignant lymphoma is reviewed and compared to the current status of conventional chemotherapy. Based on the reviewed literature, it is concluded that marrow transplantation and conventional chemoradiotherapy are not mutually exclusive and that for most young patients with acute hematological malignancies the question is not if, but rather when to intervene with a marrow transplant treatment. Thus marrow transplantation and conventional chemoradiotherapy can work as complimentary units in the complex therapeutic approach needed to cure most patients with hematological malignancies.
Bone marrow transplantation—The Marsden experience
Authors: Helenglass G. , Lakhani A. , Powles R. , Nandi A. , Zuiable A. , Gore M. , Forgeson G. , Treleaven J. , Milliken S. , Millar J. 
Published: February 2007

AbstractAllogeneic bone marrow transplantation (BMT) was first successful at the Royal Marsden Hospital in 1973 and although the programme was initially centred around treating aplastic anaemia, we soon applied the technique to acute leukaemia. Since then we have undertaken approximately 500 bone marrow transplants. This short review will cover some aspects of our programme.
The potential value of very intensive therapy with autologous bone marrow rescue in the treatment of malignant lymphomas
Authors: Gribben J. G. , Hudson B. Vaughan , Linch D. C. 
Published: February 2007

AbstractAutologous bone marrow transplantation (ABMT) following intensive therapy regimes is being used increasingly in relapsed lymphomas. To date no randomised studies have been performed to ascertain the value of this form of therapy. We describe here our experience of ABMT in both Hodgkin's disease and Non‐Hodgkin's Lymphoma and review the situations in which we believe future randomised studies should be based.